ID

11320

Beschreibung

Study documentation part: Screening This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.

Stichworte

  1. 6/30/15 6/30/15 -
Hochgeladen am

June 30, 2015

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0 Legacy

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

Subject details
Beschreibung

Subject details

Subject number:
Beschreibung

Subject number

Datentyp

integer

Alias
UMLS CUI-1
C1709561
Subject initial:
Beschreibung

Subject initial

Datentyp

text

Alias
UMLS CUI-1
C2986440
Visit date:
Beschreibung

Visit date

Datentyp

date

Alias
UMLS CUI-1
C0011008
UMLS CUI-2
C0545082
Demographics
Beschreibung

Demographics

Alias
UMLS CUI-1
C1704791
Date of birth:
Beschreibung

Date of birth

Datentyp

date

Alias
UMLS CUI-1
C0421451
Gender at birth:
Beschreibung

Gender at birth

Datentyp

text

Alias
UMLS CUI-1
C0079399
Race:
Beschreibung

Race

Datentyp

text

Alias
UMLS CUI-1
C0034510
If you chose the option "Other race" above, please specify:
Beschreibung

Other race

Datentyp

text

Alias
UMLS CUI-1
C0034510
Ethnicity (For United states only):
Beschreibung

Ethnicity (For United states only)

Datentyp

text

Informed consent
Beschreibung

Informed consent

Alias
UMLS CUI-1
C0514044
UMLS CUI-2
C0805443
Was informed consent obtained prior to any study related procedures?
Beschreibung

Was informed consent obtained prior to any study related procedures?

Datentyp

boolean

Alias
UMLS CUI-1
C0021430
If you chose "Yes" above, please enter the date subject or legally authorized representative signed informed consent.
Beschreibung

If you chose above the option "Yes", please enter the date subject or legally authorized representative signed informed consent.

Datentyp

date

Alias
UMLS CUI-1
C0011008
Eligibility criteria
Beschreibung

Eligibility criteria

Alias
UMLS CUI-1
C0332307
UMLS CUI-2
C0030705
UMLS CUI-3
C1513905
UMLS CUI-4
C1516637
Did the subject fail any eligibility criteria?
Beschreibung

Did the subject fail any eligibility criteria?

Datentyp

boolean

Alias
UMLS CUI-1
C0332307
UMLS CUI-2
C0030705
UMLS CUI-3
C1513905
UMLS CUI-4
C1516637
If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s).
Beschreibung

If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s)

Datentyp

text

Alias
UMLS CUI-1
C0231175
UMLS CUI-2
C1516637
UMLS CUI-3
C1512693
UMLS CUI-4
C0680251
Pre-randomization status
Beschreibung

Pre-randomization status

Alias
UMLS CUI-1
C0034656
UMLS CUI-2
C0449438
Will the subject be randomized?
Beschreibung

Will the subject be randomized?

Datentyp

boolean

Alias
UMLS CUI-1
C0034656
If you chose "No" above, please indicate primary reason for not being randomized?
Beschreibung

If you chose "No" above, please indicate primary reason for not being randomized?

Datentyp

text

Alias
UMLS CUI-1
C0034656
Please specify if you chose "Subject withdrew consent" , "Poor/ Non-Compliance" , "Subject no longer meets study criteria" or "Other":
Beschreibung

Please specify if you chose "Subject withdrew consent", "Poor/ Non-Compliance", "Subject no longer meets study criteria" or "Other"

Datentyp

text

Alias
UMLS CUI-1
C0392360
Please specify the date of last contact, if you chose "Lost to follow-up":
Beschreibung

Please specify the date of last contact, if you chose "Lost to follow-up".

Datentyp

date

Alias
UMLS CUI-1
C0011008
Treatment assignment
Beschreibung

Treatment assignment

Alias
UMLS CUI-1
C1522541
Please choose the treatment group the subject is assigned:
Beschreibung

Please choose the treatment group the subject is assigned.

Datentyp

text

Alias
UMLS CUI-1
C1522541
Name of the investigator:
Beschreibung

Investigator's name

Datentyp

text

Alias
UMLS CUI-1
C2346576
UMLS CUI-2
C0027365

Ähnliche Modelle

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Subject details
Subject number
Item
Subject number:
integer
C1709561 (UMLS CUI-1)
Subject initial
Item
Subject initial:
text
C2986440 (UMLS CUI-1)
Visit date
Item
Visit date:
date
C0011008 (UMLS CUI-1)
C0545082 (UMLS CUI-2)
Item Group
Demographics
C1704791 (UMLS CUI-1)
Date of birth
Item
Date of birth:
date
C0421451 (UMLS CUI-1)
Item
Gender at birth:
text
C0079399 (UMLS CUI-1)
Code List
Gender at birth:
CL Item
Male (1)
CL Item
Female (2)
Item
Race:
text
C0034510 (UMLS CUI-1)
Code List
Race:
CL Item
White (1)
CL Item
Black or African American (2)
CL Item
Asian (3)
CL Item
American Indian or Alaska Native (4)
CL Item
Native Hawaiian or Other Pacific Islander (5)
CL Item
Other Race (6)
Race
Item
If you chose the option "Other race" above, please specify:
text
C0034510 (UMLS CUI-1)
Item
Ethnicity (For United states only):
text
Code List
Ethnicity (For United states only):
CL Item
Hispanic or Latino (1)
CL Item
Not Hispanic or Latino (2)
Item Group
Informed consent
C0514044 (UMLS CUI-1)
C0805443 (UMLS CUI-2)
Informed consent
Item
Was informed consent obtained prior to any study related procedures?
boolean
C0021430 (UMLS CUI-1)
Date
Item
If you chose "Yes" above, please enter the date subject or legally authorized representative signed informed consent.
date
C0011008 (UMLS CUI-1)
Item Group
Eligibility criteria
C0332307 (UMLS CUI-1)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
Eligibility criteria
Item
Did the subject fail any eligibility criteria?
boolean
C0332307 (UMLS CUI-1)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
Failed criteria
Item
If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s).
text
C0231175 (UMLS CUI-1)
C1516637 (UMLS CUI-2)
C1512693 (UMLS CUI-3)
C0680251 (UMLS CUI-4)
Item Group
Pre-randomization status
C0034656 (UMLS CUI-1)
C0449438 (UMLS CUI-2)
Randomization
Item
Will the subject be randomized?
boolean
C0034656 (UMLS CUI-1)
Item
If you chose "No" above, please indicate primary reason for not being randomized?
text
C0034656 (UMLS CUI-1)
Code List
If you chose "No" above, please indicate primary reason for not being randomized?
CL Item
Adverse event (1)
CL Item
Subject withdrew consent (2)
CL Item
Death (3)
CL Item
Lost to follow-up (4)
CL Item
Poor/ Non-compliance (5)
CL Item
Pregnancy (6)
CL Item
Subject no longer meets study criteria (7)
CL Item
Administrative reason by sponsor (8)
CL Item
Other (9)
Reason
Item
Please specify if you chose "Subject withdrew consent" , "Poor/ Non-Compliance" , "Subject no longer meets study criteria" or "Other":
text
C0392360 (UMLS CUI-1)
Date
Item
Please specify the date of last contact, if you chose "Lost to follow-up":
date
C0011008 (UMLS CUI-1)
Item Group
Treatment assignment
C1522541 (UMLS CUI-1)
Item
Please choose the treatment group the subject is assigned:
text
C1522541 (UMLS CUI-1)
Code List
Please choose the treatment group the subject is assigned:
CL Item
70 mg twice daily (1)
CL Item
140 mg once daily (2)
Investigator's name
Item
Name of the investigator:
text
C2346576 (UMLS CUI-1)
C0027365 (UMLS CUI-2)

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video